Skip to content

What Type Of Agreement Did Sanofi And Sinopharm Sign In China ?

October 8, 2012

       Per an October 7, 2012 SeekingAlpha.com article, Sanofi and Sinopharm (China State Institute of Pharmaceutical Industry) signed a Memorandum of Understanding (MOU) in Shanghai to conduct joint research on rare diseases and treatment in China. 

         This is 1st reported in a September 28, 2012 ShanghaiDaily.com article. The purpose of this agreement is “to accelerate the translation of research results into new medicines and therapies for rare disease patients in China”. 

          As reported in several Orphan Druganaut Blog Posts, China doesn’t have an “official” definition or regulation of rare diseases and orphan drugs : 

–     Orphan Druganaut June 29, 2012 Blog Post titled,”Orphan Drugs in China”  

–      Orphan Druganaut July 14, 2012 Blog Post titled,”Rare Disease and Orphan Drug Regulations in China”  

–       Orphan Druganaut September 17, 2012 Blog Post titled,”Orphan Drugs and Patient Registries: China’s 1st Rare Disease Registry (#5)”.  

References

ChinaBioToday.com October 1, 2012 article titled,”Sanofi Signs MOU for Rare Disease Collaboration with Sinopharm” (Article available for purchase)

Copyright © 2012-2013, Ann-Teresa Cusenza and Orphan Druganaut Blog.  All rights reserved.

Advertisements

From → China, Sanofi, Sinopharm

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: